

PEDIATRIC LASSA FEVER WITH LOW CYCLE THRESHOLD VALUES AT FMC OWO ISOLATION CENTRE, NIGERIA: A CASE SERIES

Authors: Isaac Ihinmikaye¹, Chinonso Emmanuel Amadi², Ifedayo Olabisi Fasoranti³, Temitope Emmanuel Taiwo¹,
Olufemi Oladele Ayodeji¹

¹Infection Control and Research Centre, Federal Medical Centre Owo, Ondo State, Nigeria.

²Alliance for International Medical Action, Owo, Ondo State, Nigeria.

³Department of Paediatrics, Federal Medical Centre Owo, Ondo State, Nigeria.

Corresponding Author: Isaac Ihinmikaye

Email: isaacihinmikaye@gmail.com

Author's contributions

This study was a collaborative effort of the authors. The authors reviewed and approved the final version of the manuscript for publication.

Article Information

DOI: <https://doi.org/10.60787/fpj.vol2no11.207-214>

EISSN 1596-0501E

Website: <https://frontlineprofessionalsjournal.info>

Email: frontlineprofessionalsjournal@gmail.com

CITATION: Isaac Ihinmikaye, Chinonso Emmanuel Amadi, Ifedayo Olabisi Fasoranti, Temitope Emmanuel Taiwo, Olufemi Oladele Ayodeji (2025). Pediatric Lassa fever with low cycle threshold values at FMC Owo isolation centre, Nigeria: A case series. *Frontline Professionals Journal* 2(11), 207-214

ABSTRACT

Lassa fever is a zoonotic viral hemorrhagic disease endemic in West Africa region. It remains a major public health concern with Nigeria reporting most of the global cases. The reverse transcriptase polymerase chain reaction (RT-PCR) cycle threshold (CT) value is a key indicator of viral load and has been strongly linked to disease severity and poor outcomes in adults. However, little evidence exists about its prognostic significance in children, whose immune responses and recovery patterns may differ. This case series presents pediatric patients with very low CT values who nonetheless achieved full recovery following comprehensive care, challenging existing assumptions about CT values and outcomes. We reviewed the clinical profiles of three children with laboratory-confirmed Lassa fever admitted to the Federal Medical Centre (FMC) Owo Isolation Centre, Nigeria. Each received intravenous ribavirin according to national treatment protocols, alongside intensive supportive care including blood transfusions, antimicrobials, anticonvulsants, oxygen therapy, and organ support as indicated. CT values for the L and G genes were recorded at baseline and monitored during treatment. All cases were co-managed with the Pediatricians throughout admission, and received IV ribavirin in line with NCDC protocols, together with supportive care (transfusions, antimicrobials, anticonvulsants, oxygen therapy and targeted organ support as required). RT-PCR CT values (reported here as G and L genes where available) were recorded at baseline and during follow-up as part of routine clinical monitoring. Clinical data, laboratory values and documented interventions were extracted from inpatient records.

The study reported three pediatric cases of laboratory-confirmed Lassa fever managed at FMC Owo Isolation Centre, Nigeria. A 1-year-old female (baseline G18.89 and L23.37) developed seizures, anemia, and multi-organ dysfunction but recovered and discharged 31 days later following ribavirin administration, blood transfusion, and other supportive care. An 8-year-old male (baseline G-14.99 and L-19.23), experienced seizures, bleeding from puncture sites, and prolonged illness, yet was discharged after 23 days of intensive management. A 10-year-old male (baseline G-23.99 and L-27.56), had a comparatively mild course with anemia and hematuria, achieving full recovery within 16 days. In all

cases, rising CT values during treatment paralleled clinical improvement.

This is one of the first Pediatric-focused Lassa fever case series linking CT values with outcomes. CT monitoring shows promise both as a baseline prognostic marker and as a dynamic indicator of treatment response. Hence, CT monitoring should be interpreted with caution in pediatric cases. Larger studies are needed to validate Pediatric-specific cut-offs and inform triage and resource allocation in endemic settings. The findings suggest that, unlike in adults, low CT may not invariably predict poor outcomes in children. Instead, it may serve as a marker of disease severity that improves with timely antiviral therapy and multidisciplinary supportive care.

Keywords: Lassa fever, paediatric CT, FMC Owo

INTRODUCTION

Lassa fever is a zoonotic viral hemorrhagic disease caused by the Lassa virus, a member of the *Arenaviridae* family (Andersen KG, Shapiro BJ, 2015). It remains a major public health problem in West Africa, with Nigeria reporting the highest annual caseloads and frequent outbreaks. Andersen KG, Shapiro BJ, et al, 2015 The disease is transmitted primarily through exposure to rodent excreta, but human-to-human transmission also occurs, particularly in healthcare settings (Ebogo-Belobo JT, Ka'e AC, Mahamat G, Simo REG, et al.2020). Clinical presentation is highly variable, ranging from mild febrile illness to severe multi-organ dysfunction and death. The diagnosis of Lassa fever has been significantly advanced by reverse transcriptase polymerase chain reaction (RT-PCR), which not only confirms infection but also provides cycle threshold (CT) values (Kenmoe S, Tchatchouang S, 2020). These values serve as indirect measures of viral load, as demonstrated in viral infections such as SARS-CoV-2, with lower CT values indicating higher viral burden (Olumuyiwa B. Salu, Ayorinde B 2016)

Several studies in adult populations have shown that very low CT values are strongly associated with severe disease, complications, and increased mortality. Consequently, CT has been proposed as a prognostic marker to guide risk stratification and clinical management (Olumuyiwa B. Salu, Ayorinde B, et al, 2016) However, in pediatric patients, the relationship between CT values and outcomes is less clear. Children often display unique immune responses and disease trajectories compared with adults, and evidence from other viral infections, such as SARS-CoV-2, has shown differing patterns of CT–outcome associations (Olumuyiwa B. Salu, Ayorinde B, 2023). This knowledge gap poses a challenge in clinical decision-making, as children may present with high viral loads yet experience outcomes that diverge from those observed in adults. In this context, we present a descriptive case series of three pediatric patients with confirmed Lassa fever managed at the Federal Medical Centre (FMC) Owo Isolation Centre. Despite very low baseline CT values suggestive of high viral load, all three children survived following timely ribavirin therapy and comprehensive supportive care. This report highlights the potential differences in the prognostic implications of CT values in pediatric populations and underscores the importance of cautious interpretation when managing children with Lassa fever.

Lassa fever being a zoonotic viral hemorrhagic disease endemic in West Africa, with Nigeria reporting the highest global burden of infections each year. The disease is primarily transmitted through exposure to rodent excreta or contaminated food sources, although human-to-human transmission may occur, especially in healthcare settings (Andersen et al., 2015; Ebogo-Belobo et al., 2020). Clinically, its presentation ranges from mild febrile illness to severe multi-organ dysfunction and death, posing a persistent public health challenge in endemic regions (Kenmoe et al., 2020). Diagnostic advances, particularly the introduction of reverse transcriptase polymerase chain reaction (RT-PCR), have transformed the detection and monitoring of Lassa fever. Beyond confirming infection, RT-PCR provides cycle threshold (CT) values, which serve as indirect measures of viral load—with lower CT values indicating higher viral burdens (Olumuyiwa et al., 2019). In adult populations, low CT values (typically <20) have been consistently associated with severe disease, organ failure, and higher mortality rates (Strampe et al., 2021; Duvignaud et al., 2021). Consequently, CT monitoring has become an emerging prognostic tool in adult Lassa fever management, helping guide triage and therapeutic interventions.

However, the prognostic significance of CT values in pediatric patients remains poorly understood. Children often display distinct immune and recovery patterns, which may lead to different clinical trajectories compared to adults (Gentile et al., 2022; Finks et al., 2023). Evidence from other viral infections, such as SARS-CoV-2, supports these

differences, showing that children can exhibit high viral loads without corresponding severe outcomes. This discrepancy highlights a critical knowledge gap in pediatric Lassa fever care, as clinicians lack clear evidence-based CT cut-offs for risk prediction in children.

The recent case series from the Federal Medical Centre (FMC), Owo, Nigeria, provides novel insights into this issue. The study reported three pediatric cases of laboratory-confirmed Lassa fever with very low baseline CT values—indicating high viral loads—yet all three children achieved full recovery following prompt ribavirin therapy and comprehensive supportive care (Isaac et al., 2025). These findings challenge the conventional interpretation of CT values derived from adult studies, suggesting that in pediatric cases, CT may serve as a marker of disease severity rather than prognosis. The study underscores the need for larger, pediatric-focused investigations to establish CT-based risk stratification tools and guide management protocols in endemic regions.

Study Design

This was a retrospective case series describing pediatric patients with laboratory-confirmed Lassa fever managed at the Federal Medical Centre (FMC), Owo Isolation Centre, Ondo State, Nigeria. The study reviewed existing inpatient records, laboratory results, and treatment data to explore the relationship between RT-PCR cycle threshold (CT) values and clinical outcomes in children.

Ethical Considerations

This study was conducted as a retrospective review of routinely collected clinical data. The hospital management and infection control unit approved data use for research purposes, and all patient information was anonymized. Formal ethical approval was waived in line with institutional and national guidelines for retrospective descriptive studies.

CASE ONE

A 1-year-old female was referred from the Children's Emergency Room (CHER) with a confirmed diagnosis of Lassa fever, following a positive Lassa virus PCR. The patient's clinical course was marked by significant complications, including encephalitis, anemia, and disseminated intravascular coagulation (DIC). The patient's illness began two weeks prior to admission with a persistent fever, followed by a week history of cough with associated dyspnea and two episodes of generalized tonic-clonic seizures at CHER. A notable history of household rodent exposure was reported, but no known contact with sick individuals. She had initially received supportive care at a peripheral facility without improvement. Her initial Lassa virus PCR cycle threshold (CT) values were G-18.89 and L-23.37, indicating a high viral load. On admission, she was febrile (38.1°C), pale (++), had active bleeding from venipuncture sites, and an oxygen saturation (SpO₂) of 91% in room air. Other systemic findings were normal. A presumptive diagnosis of Lassa fever with multi-organ complications, including anemia, encephalitis, and DIC, was established. She was started on IV ribavirin, IV Vitamin K, IV antibiotics (ceftriaxone), intranasal oxygen at 2L/min (saturation improved to 96%) and samples for baseline laboratory investigations including a full blood count (FBC), electrolytes/urea/creatinine (E/U/Cr), liver function tests (LFT), and serology were collected, the pediatricians were invited to co-manage the patient. The fever persisted on the second day of hospitalization; the patient was noticed to have altered sensorium. Laboratory results revealed a hematocrit (HCT) of 23% and a white blood cell (WBC) count of $29.35 \times 10^9/L$, BUN of 9.9mmol/l, CRE of 287umol/l, ALP-609 I.U/L, ALT-256 I.U/L AST-701I.U/L, ALB-23g/L TP-50g/dL serology (RVS, HBsAg,) and VDRL were negative.

A subsequent seizure episode on the third day was aborted with IV diazepam, and she received a transfusion of 220 mL of fresh unbanked whole blood. By the fourth day, saturation improved to 97% in room air, she was then weaned off oxygen. Given the clinical context in an endemic region, she was also started on oral artemisinin-based combination therapy (ACT) for presumptive malaria following persistent fever. Her post-transfusion hematocrit on the fifth day was 36.8%, with a platelet count of $98 \times 10^3/UL$ and a WBC count of $16.56 \times 10^9/L$, BUN 7.3mmol/l, CRE 89umol/l, ALB 26gdl, TP 65g/dl, AST 1181I.U/l. A drastic drop in hematocrit to 11% on the seventh day necessitated a second transfusion of 220 mL of fresh unbanked whole blood.

The patient had two additional episodes of generalized seizures on the ninth day, which were again aborted with IV diazepam. IV phenobarbitone was initiated at a maintenance dose to prevent further episodes. She received another 220 mL of fresh unbanked whole blood. The following day, she was transfused with 198 mL of fresh unbanked blood. She remained febrile (37.8°C) and developed loose, bloody stools, prompting a switch in antibiotics to IV ciprofloxacin. Oral zinc and Vitamin A were also commenced. On the twelfth day, the patient's condition worsened with the development of cough and multiple seizures. Her oxygen saturation dropped to 83% in room air. She was recommenced on intranasal oxygen at 4L/min oxygen saturation improved to 96%. IV ribavirin was extended for five days. A positive malaria rapid diagnostic test (RDT) on the fifteenth day led to the initiation of oral Piperaquine dihydroartemisinin. A follow-up PCR on the seventeenth day showed a decrease in viral load (CT values of 31.92 and 35.11 following five days of IV ribavirin extension). Her ribavirin treatment was further extended for an additional 5 days. She remained thrombocytopenic (PLT $24 \times 10^3/\text{ul}$) for which she was transfused with platelet concentrate to address the critical platelet count. On the nineteenth day, her platelet count was noticed to be critically low at $9 \times 10^3/\text{UL}$ for which she was transfused with fresh plasma. By the twenty-first day, her platelet count had recovered to $194 \times 10^3/\text{UL}$, HCT was 29% and the fever had finally subsided. She received a final transfusion of 220mls of fresh whole blood. A repeat Lassa virus PCR on the twenty second day showed a CT value of 36.9 (Single L gene), indicating a significant reduction in viral load she then commenced oral ribavirin for five days. A post-transfusion HCT on the twenty-third day was 50% PLT of $240 \times 10^3/\text{ul}$. A left gluteal abscess was noted; the plastic surgery team was consulted for co-management. A repeat Lassa PCR on the 31st day was negative, confirming viral clearance. She was transferred to the pediatric ward for incision and drainage (I&D) of the abscess and was subsequently discharged with a scheduled follow-up at the Viral Hemorrhagic Fever (VHF) clinic.

CASE TWO

An 8-year-old male who was transferred from the Infectious Disease Hospital (IDH) Akure to the Infection Control and Research Centre (ICRC) Owo after a positive Lassa virus PCR result with cycle threshold (CT) values (G-14.99 and L-19.23). He presented with a two-week history of fever, reduced urine output, and bleeding from puncture sites. He also reported a cough and loose stools. A history of frequent rodent sightings at home suggested a probable source of infection. There was no known contact with sick individuals.

On admission, the patient was febrile (38.8°C), tachycardic (pulse rate of 127 bpm), and tachypneic (respiratory rate of 50 breaths/min), with signs of respiratory distress. He had an oxygen saturation (SpO₂) of 97% on intranasal oxygen at 2 L/min. A working diagnosis of Lassa fever with complications of acute kidney injury (AKI) and disseminated intravascular coagulation (DIC) was made.

Intravenous Ribavirin, broad-spectrum antibiotics (intravenous ceftriaxone), vitamin K, tranexamic acid, and Intravenous fluids were commenced immediately. Sample for baseline investigations were obtained. Pediatricians were invited to co-manage the patient.

By Day 2, laboratory results revealed marked leukocytosis ($51.8 \times 10^9/\text{L}$), His hematocrit was 32.1%, he had deranged liver function tests; ALP-1330I.U/l, AST-314I.U/l, AST-615 I.U/l, TBIL- 3.5umol/l, ALB-20g/l; he also had an elevated serum creatinine of 204μmol/L, BUN of 8.0mmol/l, serum potassium of 3.2mmol/l, Bicarbonate of 18mmol/l.

By Day 3, the patient's condition worsened with a drop in hematocrit to 25%, necessitating a fresh whole blood transfusion. Other repeat FBC result revealed a WBC of $23.08 \times 10^3/\text{ul}$, PLT of $229 \times 10^3/\text{ul}$, E/U/CR revealed a CRE 238umol/l, BUN 9.4mmol/l, bicarbonates of 18mmol/l, potassium of 3.18mmol/l, and sodium of 130mmol/l.

On the fifth day, there was noticed to be a drop in WBC to $15.7 \times 10^3/\text{ul}$, hematocrit was 27%, PLT remained within normal range of $273 \times 10^3/\text{ul}$, potassium improved to 4mmol/l, sodium-138mmol/l, bicarbonates-21mmol/l, CRE-146umol/l, BUN-9.2mmol/l. ALP-277I.U/l, ALT-207 I.U/l, AST-471iu/l, ALB-21 g/l, TP-44g/dl. He was transfused with whole blood. The post transfusion hematocrit being 37%.

Persistent fever and poor clinical state prompted the addition of IV dexamethasone to his regimen on Day 7.

On the 12th day, he was noticed to be pale, had several episodes of seizure, a repeat hematocrit was 25% and low serum albumin (24g/L). He had a repeat blood transfusion, and IV ribavirin was extended for an additional five days. Nutritional support was optimized, while seizures were controlled by the administration of parenteral phenobarbitone.

The patient's condition gradually improved over the following days. On Day 17, a repeat Lassa virus PCR showed a significant increase in CT values (35.35 and 36.29), indicating a substantial reduction in viral load. He then had a second extension of IV ribavirin for additional five days. On Day 20, he had been seizure-free for five days, and his vital signs were stable, he was weaned off oxygen, intravenous fluids were discontinued, and oral fluid intake was encouraged. By Day 23, he was clinically stable. A repeat PCR revealed a CT value of 37.00. He was discharged on oral ribavirin and scheduled for a follow-up at the Viral Hemorrhagic Fever (VHF) clinic. A subsequent PCR test two weeks later was negative, confirming viral clearance.

Due to the multiple seizure episodes and the potential for neurological sequelae, he was referred to a pediatric neurologist for ongoing care and monitoring.

CASE THREE:

A 10-year-old male who was referred from a primary health care (MCHC) to the Infection Control and Research Centre (ICRC) with a confirmed positive Lassa virus PCR test (cycle threshold (CT) value of G23.99 and L27.56). His illness began with a 9-day history of intermittent high-grade fever, followed by a 3-day history of generalized body weakness, abdominal pain, and passage of dark, coke-colored urine. There was no history of vomiting, diarrhea, or bleeding from any orifices. His past medical history was unremarkable, and while there was no known contact with sick individuals, there was a history of rodent infestation at his home.

On admission, the patient was febrile (38.4°C) and pale. The systemic examination was otherwise normal. A provisional diagnosis of Lassa fever complicated by anemia was made. Samples for baseline laboratory investigations, including a full blood count, electrolytes, urea and creatinine, and liver function were obtained. Consult was sent to the pediatricians who comanaged the patient.

Base line investigation results revealed a HCT of 28.8%, prompting a transfusion of 250 mL of fresh whole blood. His platelet count was $161 \times 10^3/\text{UL}$ and white blood cell count was $15.46 \times 10^3/\text{UL}$, while kidney function tests revealed Cr 115 $\mu\text{mol/l}$, BUN 7.6 mmol/l , electrolytes revealed sodium of 138 mmol/l , potassium of 3.6 mmol/l , bicarbonates of 22 mmol/l . liver function tests revealed ALP 167 I.U/L , ALT 203 i.u/l , AST 561 i.u/l , ALB 40.1 g/l He was immediately started on intravenous ribavirin and supportive treatment including intravenous 4.3% dextrose in saline (500 mL 12-hourly), oral zinc (20 mg daily), and oral vitamin K (5 mg daily).

On Day 2, the patient remained febrile with no new complaints. His urine remained coke-colored, and a dipstick test confirmed the presence of hematuria and proteinuria. On Day 3, the patient became afebrile, and hematuria was improving although urinalysis still showed microscopic hematuria. A post-transfusion HCT was 33%. He was stable and maintained on the same treatment.

Sixth day into admission, he developed new symptoms of vomiting and mild abdominal pain. Intravenous antiemetics and oral omeprazole (20 mg daily) were added to his regimen. His temperature remained normal. On Day 9, he was noticed to be pale, and a repeat PCV was 23.5%, necessitating a second transfusion of fresh whole blood at 20 ml/kg . Post-transfusion HCT on Day 10 was 33%, and intravenous fluids were discontinued. His urine became clearer by Day 11. A repeat Lassa virus PCR showed improved CT values of 34.55 and 34.76, indicating a lower viral load. IV ribavirin was then extended for additional five days. The patient's clinical condition improved significantly. Intravenous tranexamic acid was discontinued on the 14th day when urinalysis revealed a normal result. A final PCR test was performed on Day 16 and revealed a negative result for the Lassa virus. The patient was stable with no further symptoms.

The patient was discharged on Day 17 to continue follow-up care at a Viral Hemorrhagic Fever (VHF) clinic. An appointment was scheduled for one-week post-discharge.


RESULTS SUMMARY

All three patients presented with very low baseline CT values, indicating high viral loads—ranging from G: 14.9–23.9 and L: 19.2–27.6. Despite this, all achieved full recovery. The first patient, a 1-year-old female with multi-organ dysfunction and disseminated intravascular coagulation, required multiple transfusions, oxygen therapy, and extended ribavirin treatment. Her CT values increased progressively from G18.89/L23.37 to >36, paralleling steady clinical improvement until viral clearance was confirmed on Day 31.

The second case, an 8-year-old male with acute kidney injury and recurrent seizures, also required prolonged hospitalization and ribavirin extension. His CT values rose from G14.99/L19.23 to 37.00 by Day 23, coinciding with complete recovery.

The third patient, a 10-year-old male with mild anemia and hematuria, had the shortest course. His CT values improved from G23.99/L27.56 to >34 within 11 days, and he achieved viral clearance by Day 16.

Across all cases, rising CT values consistently mirrored clinical recovery and declining symptom severity. No fatalities or long-term complications were recorded at discharge



DISCUSSION

This case series highlights the prognostic relevance of CT values in pediatric Lassa fever. A consistent pattern emerged: lower baseline CT values were linked with more severe complications and prolonged convalescence, while higher CT values correlated with milder disease. Progressive increases in CT values during treatment paralleled clinical recovery, underscoring their utility as a real-time marker of viral clearance. Previous adult studies have consistently demonstrated that very low RT-PCR cycle threshold (CT) values (<20) are associated with markedly high mortality rates—often between 80% and 90%—reflecting severe viral replication and poor prognostic outcomes (Duvignaud et al., 2021; Strampe et al., 2021). In these adult cohorts, lower CT values have been used as a critical prognostic marker, guiding aggressive management and early escalation of care. In contrast, the present pediatric case series from FMC Owo reveals a strikingly different pattern. Despite baseline CT values well below 20—indicative of high viral loads—all three children achieved complete recovery following prompt administration of ribavirin and intensive supportive care (Isaac et al., 2025). This divergence suggests that, unlike adults, children may tolerate higher viral burdens without fatal outcomes, possibly due to differences in immune modulation, disease trajectory, and resilience of organ systems. These findings highlight the need for pediatric-specific prognostic frameworks for interpreting CT values in Lassa fever.

Although adult-focused studies have linked baseline CT values below 20 with poor outcomes and high mortality, our findings suggest that in children, such values are not invariably fatal. Two patients with baseline CT values <20 developed life-threatening complications, yet survived with timely IV ribavirin and intensive supportive care. This underscores that CT values should be interpreted as part of a broader risk stratification framework, rather than as stand-alone predictors. Factors such as host immunity, nutritional status, co-infections, and access to high-quality supportive care critically modify outcomes (Duvignaud A, Jaspard M, Etafo IC, 2021). Furthermore, pediatric immune responses and recovery potential may differ from adults, which may explain the observed divergence.

Clinically, CT values could serve as a vital triage tool in resource-limited endemic settings. They can enable healthcare providers to swiftly identify high-risk pediatric patients, prioritize intensive monitoring, and strategically allocate scarce resources such as antivirals, transfusions, and advanced supportive care.

CONCLUSION

It is worth noting to state that while CT values have potential as prognostic indicators, clinical correlation remains essential, particularly in pediatric management. In this pediatric Lassa fever case series, low baseline CT values were associated with greater severity, while higher values corresponded with milder disease. Importantly, despite adult data linking CT <20 with high mortality, all patients in this series survived, indicating that in children, CT may be a marker of severity but not an absolute determinant of outcome. Rising CT values during treatment reliably tracked clinical recovery, reinforcing their value as a dynamic prognostic tool. These findings suggest that favorable outcomes are achievable even in children with high viral load when comprehensive, multidisciplinary care is provided. CT monitoring may therefore provide a pragmatic framework for risk stratification in endemic settings, though validation in larger pediatric cohorts remains essential. Beyond clinical management, preventive strategies remain critical. Regular community-wide deratization and sensitization campaigns focusing on environmental sanitation, safe food storage, and household hygiene are strongly recommended to reduce rodent-to-human transmission and mitigate recurrent outbreaks.

RECOMMENDATIONS:

Integrate CT Monitoring into Routine Pediatric Care

Cycle threshold (CT) values should be incorporated into standard pediatric Lassa fever management protocols. Regular CT monitoring can help track treatment response and guide the optimal duration of ribavirin therapy, ensuring timely clinical decisions. There is a need to have inclusion of CT tracking in national pediatric Lassa protocols.

Avoid Overreliance on CT as a Sole Prognostic Tool

While CT values provide important insights into viral load, they should not be used in isolation to predict disease outcome in children. Clinicians should interpret CT results alongside the patient's clinical presentation, laboratory findings, and response to therapy.

Strengthen Pediatric-Specific Research and Guidelines

Larger, multicenter studies are needed to establish pediatric-specific CT value cut-offs for risk stratification. Evidence from such studies will help refine national and regional guidelines on Lassa fever management in children.

Enhance Capacity for Comprehensive Supportive Care

Early access to ribavirin, blood transfusion services, anticonvulsants, and oxygen therapy significantly improved outcomes in this series. Hospitals in endemic regions should strengthen their capacity for integrated, multidisciplinary care for pediatric Lassa fever patients.

Promote Community-Based Prevention and Early Presentation

Community education should emphasize environmental hygiene, safe food storage, and rodent control to reduce transmission. Parents and caregivers should also be sensitized to seek early medical attention for febrile illnesses in children, especially in endemic areas.

Establishing standardized CT interpretation thresholds across laboratories.

Expanding access to RT-PCR testing and training healthcare workers in result interpretation will improve diagnostic accuracy, monitoring, and patient outcomes across treatment centers

Limitations: This study has limitations. It is a small descriptive series, limiting the generalizability of our findings. Additionally, CT values may vary across laboratories due to differences in assay protocols and reagents.⁶ Finally, as a descriptive study, it does not allow for statistical inference.

Acknowledgement:

The authors express their profound gratitude to the Federal Medical Centre (FMC) Owo Management, particularly the leadership of the Infection Control and Research Centre, for providing the enabling environment to conduct this study. Special appreciation goes to the Paediatrics Department for their unwavering collaboration and expert co-management of the patients, and to the dedicated frontline healthcare workers at the Lassa Fever Isolation Ward, whose commitment and courage made the successful management of these cases possible. We also acknowledge the invaluable support of the Nigeria Centre for Disease Control (NCDC) for continuous surveillance and technical guidance in Lassa fever control efforts. Finally, we thank the patients and their families for their cooperation and trust throughout the treatment process, without which this work would not have been possible.

Conflict of Interest

The authors declare no conflict of interest to this study.

All authors contributed to the conception, data collection, analysis, and manuscript preparation independently, without any financial or personal relationships that could have influenced the work.

No external funding or sponsorship was received for this research.

References

- Andersen, K. G., Shapiro, B. J., Matranga, C. B., Sealfon, R., Lin, A. E., Moses, L. M., et al. (2015, August 17). Clinical sequencing uncovers origins and evolution of Lassa virus. *Cell*, 162(4), 738.
- Duvignaud, A., Jaspard, M., Etafo, I. C., Gabillard, D., Serra, B., Abejegah, C., et al. (2021, April 1). Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): A prospective cohort study. *The Lancet Global Health*, 9(4), e469–e478. [https://doi.org/10.1016/S2214-109X\(21\)00038-9](https://doi.org/10.1016/S2214-109X(21)00038-9)
- Finks, S. W., Van Matre, E., Budd, W., Lemley, E., Ray, N. K., Mahon, M., et al. (2023, December). Clinical significance of quantitative viral load in patients positive for SARS-CoV-2. *American Journal of Medicine Open*, 10(1), 100050. <https://doi.org/10.1016/j.ajmo.2023.100050>
- Gentile, A., Juarez, M. D. V., Lucion, M. F., Pejito, M. N., Alexay, S., Orqueda, A. S., et al. (2022, August 1). COVID-19 in children: Correlation between epidemiologic, clinical characteristics, and RT-qPCR cycle threshold values. *Pediatric Infectious Disease Journal*, 41(8), 666–672. <https://doi.org/10.1097/INF.0000000000003541>
- Kenmoe, S., Tchatchouang, S., Ebogo-Belobo, J. T., Ka'e, A. C., Mahamat, G., Simo, R. E. G., et al. (2020, August 1). Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents, and other mammals in sub-Saharan Africa. *PLoS Neglected Tropical Diseases*, 14(8), e0008589. <https://doi.org/10.1371/journal.pntd.0008589>
- Olumuyiwa, B. S., Ayorinde, B. J., Honoré, S. B., Jijoho, M. A., Magloire, D. S., Fernand, G., & Christian, F. L. S. (2019). Molecular confirmation and phylogeny of Lassa fever virus in Benin Republic, 2014–2016. *African Journal of Laboratory Medicine*, 8(1), 803. <https://doi.org/10.4102/ajlm.v8i1.803>
- Strampe, J., Asogun, D. A., Speranza, E., Pahlmann, M., Soucy, A., Bockholt, S., et al. (2021, June 1). Factors associated with progression to death in patients with Lassa fever in Nigeria: An observational study. *The Lancet Infectious Diseases*, 21(6), 876–886. [https://doi.org/10.1016/S1473-3099\(20\)30868-4](https://doi.org/10.1016/S1473-3099(20)30868-4)